Thera-SAbDab

GOCATAMIG1

>   Structural Summary
TherapeuticGocatamig1
Target 1CD3E
Heavy Chain 1EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAINWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSS
Light Chain 1QTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCTLWYSNRWVFGGGTKLTVL
100% seqID Fv 1 StructureNone
99% seqID Fv 1 StructureNone
95-98% seqID Fv 1 StructureNone
Target 2ALB
Heavy Chain 2EVQLVESGGGLVQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVTVSS
Light Chain 2na
100% seqID Fv 2 StructureNone
99% seqID Fv 2 StructureNone
95-98% seqID Fv 2 Structure8z8v [Fvs: B]
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Gocatamig1.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 97.39%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 101 102 103 104 105 106 107 108 109 110 111 112 113
gocatamig1_Fv2 E V Q L V E S G G G L V Q P G N S L R L S C A A S G F T F S K F G M S W V R Q A P G K G L E W V S S I S G S G R D T L Y A D S V K G R F T I S R D N A K T T L Y L Q M N S L R P E D T A V Y Y C T I G G S L S V S S Q G T L V T V S S
8z8v E V Q L V E S G G G L V Q P G N S L R L S C A A S G F T F S S F G M S W V R Q A P G K G L E W V S S I S G S G S D T L Y A D S V K G R F T I S R D N A K T T L Y L Q M N S L R P E D T A V Y Y C T I G G S L S R S S Q G T L V T V S S
>   Metadata
FormatTrispecific Mixed scFv and Single Domains (scFvhl-VH-VH'); Bispecific entry
Isotypena;na
Highest Clinical Trial (Feb '25)Phase-I/II
Estimated Status (Feb '25)Active
Recorded Developmental Technology
INN Year Proposed2024
INN Year Recommended2024
Companies InvolvedHarpoon Therapeutics
Conditions Approvedna
Conditions ActiveNeuroendocrine tumours, Small cell lung cancer
Conditions Discontinuedna
NotesHumanised Fv1: musmus/homosap. Podentamig VH2 and Godatamig VH2 have the same sequence

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy